JP2012197278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012197278A5 JP2012197278A5 JP2012091882A JP2012091882A JP2012197278A5 JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5 JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antigen
- binding portion
- tumor cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (3)
- a)腫瘍細胞の表面上に存在するネイティブ形態の前立腺特異的膜抗原に結合し、
b)腫瘍細胞によって内在化でき、
c)LNCAP細胞には結合するが、前立腺膜特異的抗原の発現を欠く細胞には実質的に結合せず、
d)T細胞レセプター複合体のCD3鎖に結合し、
e)配列番号:11〜配列番号:16の配列を有するCDR、または、図20-1〜図20-2に示されるCDR H1、CDR H2、CDR H3、CDR L1、CDR L2およびCDR L3と称されるCDR、または、図21-1〜図21-2に示されるCDR H1、CDR H2、CDR H3、CDR L1、CDR L2およびCDR L3と称されるCDRを含むことを特徴とする、
ダイアボディであるモノクローナル抗体の抗原結合部分。 - 前記ダイアボディは、T細胞媒介性細胞傷害性を方向変換することによって腫瘍細胞の溶解が誘導されるものである、請求項1に記載の抗原結合部分。
- 請求項1または2に記載の抗原結合部分を含む、医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05011536A EP1726650A1 (en) | 2005-05-27 | 2005-05-27 | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
EP05011536.9 | 2005-05-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008512701A Division JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014017392A Division JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012197278A JP2012197278A (ja) | 2012-10-18 |
JP2012197278A5 true JP2012197278A5 (ja) | 2013-12-05 |
JP5524270B2 JP5524270B2 (ja) | 2014-06-18 |
Family
ID=34937022
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008512701A Active JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
JP2012091882A Active JP5524270B2 (ja) | 2005-05-27 | 2012-04-13 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
JP2014017392A Active JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
JP2016063219A Pending JP2016190839A (ja) | 2005-05-27 | 2016-03-28 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008512701A Active JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014017392A Active JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
JP2016063219A Pending JP2016190839A (ja) | 2005-05-27 | 2016-03-28 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Country Status (16)
Country | Link |
---|---|
US (3) | US8198416B2 (ja) |
EP (3) | EP1726650A1 (ja) |
JP (4) | JP5038297B2 (ja) |
CN (1) | CN101233236B (ja) |
AT (1) | ATE505544T1 (ja) |
AU (1) | AU2006251445B2 (ja) |
CA (1) | CA2609682C (ja) |
CY (1) | CY1111409T1 (ja) |
DE (1) | DE602006021296D1 (ja) |
DK (1) | DK1883698T4 (ja) |
ES (1) | ES2362795T5 (ja) |
PL (1) | PL1883698T5 (ja) |
PT (1) | PT1883698E (ja) |
RU (1) | RU2458073C2 (ja) |
SI (1) | SI1883698T2 (ja) |
WO (1) | WO2006125481A1 (ja) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
EP3184539A3 (en) | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antibodies |
EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
GB0715542D0 (en) * | 2007-08-09 | 2007-09-19 | Imp Innovations Ltd | Methods |
SG186017A1 (en) | 2007-11-30 | 2012-12-28 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
US20110189093A1 (en) * | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
ITTO20080313A1 (it) * | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
PL2356153T3 (pl) * | 2008-10-01 | 2016-11-30 | Swoiste międzygatunkowo dwuswoiste przeciwciało jednołańcuchowe PSMAXCD3 | |
CA2738566C (en) | 2008-10-01 | 2024-04-30 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
EP3495000A1 (en) * | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
TWI629357B (zh) * | 2009-10-02 | 2018-07-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種特異性的PSMAxCD3雙特異性單鏈抗體 |
MX354143B (es) * | 2009-12-02 | 2018-02-14 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso. |
TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
WO2013155605A1 (en) * | 2012-04-19 | 2013-10-24 | Innovascreen Inc. | Method for predicting a pathophysiological condition in an animal |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
US10711282B2 (en) | 2015-11-23 | 2020-07-14 | Novartis Ag | Optimized lentiviral transfer vectors and uses thereof |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
CN105504061A (zh) * | 2016-02-03 | 2016-04-20 | 南昌大学 | 针对前列腺特异性膜抗原的纳米抗体 |
CN105968201A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原的单域重链抗体 |
CN105542009A (zh) * | 2016-02-03 | 2016-05-04 | 南昌大学 | 一种针对前列腺特异性膜抗原的单域重链抗体 |
CN105968202A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原胞外区的单域重链抗体 |
CN105524171A (zh) * | 2016-02-03 | 2016-04-27 | 中国人民解放军第三军医大学第三附属医院 | 一种针对前列腺特异性膜抗原的纳米抗体 |
CN105968203A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
KR20220133318A (ko) | 2016-04-15 | 2022-10-04 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
RU2019105693A (ru) | 2016-08-01 | 2020-09-01 | Новартис Аг | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага |
EP3544997A4 (en) * | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
CN111566124A (zh) | 2017-10-25 | 2020-08-21 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
MX2020006155A (es) | 2017-12-12 | 2020-08-13 | Macrogenics Inc | Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades. |
EP3773740A1 (en) | 2018-04-13 | 2021-02-17 | Heidelberg Pharma Research GmbH | Targeted amatoxin conjugate for the treatment of solid tumors |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
EP3587454A1 (en) * | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
EP3830132B1 (en) | 2018-07-31 | 2022-11-23 | Heidelberg Pharma Research GmbH | Humanized antibodies against psma |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
CN113329792A (zh) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN110407939B (zh) * | 2019-03-12 | 2023-09-29 | 广东医科大学附属第二医院 | 一种人源化抗psma单链抗体及其应用 |
EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
EP3842461A1 (en) | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
TW202132353A (zh) * | 2020-02-18 | 2021-09-01 | 大陸商和鉑醫藥(上海)有限責任公司 | 一種分離的結合抗原psma的蛋白及其用途 |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
JP7390214B2 (ja) | 2020-02-28 | 2023-12-01 | 株式会社東京精密 | シリコンウエハ表面状態診断方法及び表面改質方法 |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
AU6139794A (en) * | 1993-02-10 | 1994-08-29 | Unilever Plc | Immobilized proteins with specific binding capacities and their use in processes and products |
ES2260788T3 (es) * | 1996-03-25 | 2006-11-01 | Medarex, Inc. | Anticuerpos monoclonales especificos para el dominio estracelular de antigeno de membrana especifico de la prostata. |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
HUP0001441A3 (en) * | 1997-02-26 | 2001-03-28 | Sankyo Company Ltd Chuo Ku | Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives |
US6258939B1 (en) * | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
IL147638A0 (en) * | 1999-07-29 | 2002-08-14 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen |
FR2797743B1 (fr) * | 1999-08-23 | 2003-08-08 | Urogene | Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal |
MXPA03010804A (es) * | 2001-06-01 | 2004-11-22 | Cornell Res Foundation Inc | Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos. |
WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
IL159422A0 (en) * | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
EP3184539A3 (en) * | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antibodies |
BR0307216A (pt) * | 2002-01-28 | 2005-12-20 | Medarex Inc | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) |
JP2004000045A (ja) * | 2002-05-31 | 2004-01-08 | Kyowa Hakko Kogyo Co Ltd | 前立腺特異的膜抗原に対する抗体 |
US6641899B1 (en) * | 2002-11-05 | 2003-11-04 | International Business Machines Corporation | Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same |
CA2514419A1 (en) * | 2003-01-28 | 2004-08-12 | Proscan Rx Pharma Inc. | Prostate cancer diagnosis and treatment |
EP1841467A4 (en) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES |
ES2386366T3 (es) * | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
JP5249587B2 (ja) * | 2005-02-18 | 2013-07-31 | メダレックス, インク. | フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体 |
JP2008535865A (ja) * | 2005-04-08 | 2008-09-04 | サイトジェン コーポレーション | 抗psmaコンジュゲート抗体 |
EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
PL1912677T3 (pl) * | 2005-06-20 | 2014-03-31 | Psma Dev Company L L C | Koniugaty przeciwciało PSMA-lek |
-
2005
- 2005-05-27 EP EP05011536A patent/EP1726650A1/en not_active Withdrawn
-
2006
- 2006-03-02 WO PCT/EP2006/001917 patent/WO2006125481A1/en active Application Filing
- 2006-03-02 US US11/915,454 patent/US8198416B2/en active Active
- 2006-03-02 PL PL06707388T patent/PL1883698T5/pl unknown
- 2006-03-02 RU RU2007147596/10A patent/RU2458073C2/ru active
- 2006-03-02 EP EP11151622A patent/EP2363486A1/en not_active Ceased
- 2006-03-02 SI SI200630996T patent/SI1883698T2/sl unknown
- 2006-03-02 CA CA2609682A patent/CA2609682C/en active Active
- 2006-03-02 EP EP06707388.2A patent/EP1883698B2/en active Active
- 2006-03-02 AU AU2006251445A patent/AU2006251445B2/en active Active
- 2006-03-02 DE DE602006021296T patent/DE602006021296D1/de active Active
- 2006-03-02 ES ES06707388.2T patent/ES2362795T5/es active Active
- 2006-03-02 DK DK06707388.2T patent/DK1883698T4/en active
- 2006-03-02 JP JP2008512701A patent/JP5038297B2/ja active Active
- 2006-03-02 AT AT06707388T patent/ATE505544T1/de active
- 2006-03-02 PT PT06707388T patent/PT1883698E/pt unknown
- 2006-03-02 CN CN2006800275807A patent/CN101233236B/zh active Active
-
2011
- 2011-05-04 CY CY20111100431T patent/CY1111409T1/el unknown
-
2012
- 2012-04-13 JP JP2012091882A patent/JP5524270B2/ja active Active
- 2012-05-08 US US13/466,286 patent/US8632777B2/en active Active
-
2013
- 2013-12-13 US US14/105,808 patent/US9238694B2/en active Active
-
2014
- 2014-01-31 JP JP2014017392A patent/JP6110321B2/ja active Active
-
2016
- 2016-03-28 JP JP2016063219A patent/JP2016190839A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012197278A5 (ja) | ||
MX2021010441A (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. | |
PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
MX362705B (es) | Anticuerpos monoclonales multiespecíficos. | |
WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
WO2015092024A3 (en) | Method of engineering multi-input signal sensitive t cell for immunotherapy | |
RU2017132160A (ru) | Антитела к pd-l1 и их применение для усиления функции t-клеток | |
EA201790862A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
WO2013064701A3 (en) | Specific antibodies and their isolation with anti-idiotypic antibodies | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
WO2015054691A8 (en) | Tem8 antibodies and their use | |
WO2015127136A3 (en) | Ebola monoclonal antibodies | |
EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
NZ720765A (en) | Antibodies and methods of use | |
CR20110577A (es) | Proteínas de unión a il-1 | |
WO2014011993A3 (en) | Epitope spreading associated with car t-cells | |
JP2014509837A5 (ja) | ||
CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
JP2013539454A5 (ja) | ||
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
WO2013142300A3 (en) | Jcv neutralizing antibodies | |
EP4065164A4 (en) | ANTIBODIES AGAINST CD3 AND BCMA AND BISPECIFIC BINDING PROTEINS PRODUCED THEREOF |